The respiratory segment, often influenced by seasonal factors, registered a 1.1% increase in value but faced a 4.6% decline ...

with flagship brands such as Augmentin, Ceftum, and T-Bact gaining market share in the general medicines segment. Additionally, GSK’s innovative respiratory portfolio, led by Nucala and Trelegy ...

The pharma industry registered a 7.5% value growth year-on-year for the month of February, with sales of ₹18,781 crore, ...

Augmentin, a combination of amoxicillin and clavulanate potassium, maintained its top-selling brand status in the Indian pharmaceutical market, selling around Rs 75-80 crore per month. The strong ...

Among them, the cardiac, gastrointestinal, and antidiabetic therapies saw high value growth of 9.5 per cent, 9.6 per cent, ...

Four of the top 5 selling products of GSK are antibiotics (Augmentin, Duricef, Ceporex and Velosef). Two of them come from BMS. By having four well established - and relatively old - antibiotic ...

The initiatives to improve healthcare access — including Ayushman Bharat, which provides financial protection and better ...

Major pharmaceutical products and medicines have jumped in prices despite and executive order by President Bola Tinubu, ...

The drug shortages are the result of manufacturing problems, increased demand, and other issues.View on euronews ...

The Indian QR coding programme meant to protect domestic drug supplies has failed, and is now a gift to the counterfeiters.

GlaxoSmithKline Pharmaceuticals Limited is ... patients. It launched Augmentin ES deploying technology in reaching out to key specialists in ear, nose and throat (ENT) and Paediatrics practice.